Humacyte, Inc.
NASDAQ Global SelectTotal Valuation
Humacyte, Inc. carries a market capitalization of 233.52M, placing it among publicly traded companies globally. Its enterprise value stands at 120.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 233.52M |
| Enterprise Value | 120.82M |
Share Statistics
Humacyte, Inc. currently has 222.02M shares outstanding.
| Shares Outstanding | 222.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 51.32, and the price-to-book ratio stands at -0.14.
| PE Ratio | N/A |
| PS Ratio | 51.32 |
| PB Ratio | -0.14 |
| P/TBV Ratio | 8.90 |
| P/FCF Ratio | -1.03 |
| P/OCF Ratio | -1.02 |
Enterprise Valuation
| EV / Sales | 59.93 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Humacyte, Inc. maintains a current ratio of 3.93, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 566.94, indicating elevated leverage, while an interest coverage ratio of -10.13 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.93 |
| Quick Ratio | 3.03 |
| Debt / Equity | 566.94 |
| Debt / EBITDA | -0.62 |
| Interest Coverage | -10.13 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -71.47 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.29 |
Stock Price Statistics
Humacyte, Inc.'s stock has declined approximately -46.7433% over the past 52 weeks. The 50-day moving average sits at 0.86, while the 200-day moving average is 1.21.
| Beta (5Y) | N/A |
| 52-Week Price Change | -46.7433% |
| 50-Day Moving Average | 0.86 |
| 200-Day Moving Average | 1.21 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Humacyte, Inc. generated 2.02M in revenue and converted that into -97.59M in net income, yielding earnings per share of -0.57. EBITDA reached -106.58M, while operating income came in at -113.89M.
| Revenue | 2.02M |
| Gross Profit | -9.58M |
| Operating Income | -113.89M |
| Pretax Income | -97.59M |
| Net Income | -97.59M |
| EBITDA | -106.58M |
| EBIT | -113.89M |
| Earnings Per Share (EPS) | -0.57 |
Balance Sheet
Humacyte, Inc. holds 48.54M in cash and equivalents against 65.90M in total debt, resulting in a net debt position of -12.67M. Total book value stands at -744.44M, with working capital of 47.41M providing operational flexibility.
| Cash & Cash Equivalents | 48.54M |
| Total Debt | 65.90M |
| Net Debt | -12.67M |
| Equity (Book Value) | -744.44M |
| Book Value Per Share | -4.37 |
| Working Capital | 47.41M |
Cash Flow
Humacyte, Inc. produced -101.54M in operating cash flow over the past twelve months. After subtracting -831,000.00 in capital expenditures, free cash flow totaled -102.38M - equivalent to -0.60 per share.
| Operating Cash Flow | -101.54M |
| Capital Expenditures | -831,000.00 |
| Free Cash Flow | -102.38M |
| FCF Per Share | -0.60 |
Margins
Humacyte, Inc. operates with a gross margin of -475.05, reflecting its pricing power and cost economics. The operating margin of -5,649.21 and net profit margin of -4,840.82 provide insight into operational efficiency.
| Gross Margin | -475.05 |
| Operating Margin | -5,649.21 |
| Pretax Margin | -4,840.82 |
| Profit Margin | -4,840.82 |
| EBITDA Margin | -5,286.95 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -36.79 |
| FCF Yield | -97.34 |
Scores
Humacyte, Inc. posts an Altman Z-Score of -11.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -11.67 |